Royal Philips NV reported a net loss of €698 million for 2024, attributed mainly to a €1 billion out-of-court settlement related to sleep apnea devices in the US. The company's sales for the fourth quarter were €5.04 billion, slightly below the expected €5.07 billion, with an adjusted EBITA of €679 million against the anticipated €687 million. Despite a 1% increase in total turnover to €18 billion for the year, Philips faced a double-digit sales decline in China, offset by growth in other regions, particularly the US. For 2025, Philips forecasts comparable sales growth between 1% and 3%. The company also announced a fiscal year dividend of €0.85 per share, unchanged from the previous year, and expects free cash flow for 2025 to range between €400 million and €600 million. Philips shares dropped 11% following the earnings announcement, reflecting investor concerns over the company's performance and outlook, especially in the Chinese market.